Navigation Links
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Date:6/17/2008

chering Pharma AG, who has exclusive rights to Zevalin in all countries of the world except the U.S. CTI has now entered into an agreement with Bayer Schering Pharma to get access to this data. Under the terms of the agreement, CTI will make an initial payment to Bayer Schering Pharma with an additional payment upon FDA approval of a sBLA for Zevalin based on the FIT trial results. CTI also will pay Bayer royalties on net product sales up to a specified aggregate amount.

"We believe that gaining access to these important Zevalin trial data and regulatory documents will allow for the potential to expand the label in the U.S. to include consolidation of first-line therapy, as Bayer Schering Pharma did in Europe, and may give more patients access to the potential benefits of Zevalin," said James A. Bianco, M.D., President and CEO of Cell Therapeutics. "We are pleased with Bayer's willingness to support our efforts to potentially broaden U.S. patient access to this important therapeutic, and delighted to be working with such a talented group of dedicated healthcare professionals."

Cell Therapeutics has requested a meeting with the Food and Drug Administration (FDA) to discuss expanding the label for Zevalin in the U.S. to include consolidation following first-line treatment of follicular lymphoma based on the FIT trial data. If approved, this new indication has the potential to increase the market for Zevalin in the U.S.

About the Phase III First-line Indolent (FIT) Trial

The multinational, randomized phase III First-line Indolent Trial (FIT) evaluated the benefit and safety of a single infusion of Zevalin in patients with CD20-positive follicular lymphoma who had achieved a partial remission or a complete remission after receiving standard first-line chemotherapy regimens. The FIT trial results were presented in one oral and two poster presentations at the American Society of Hematology (ASH) conference in December 2007. The FIT trial demons
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
2. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
3. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
4. Chromos enters into loan and lending arrangements
5. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
6. CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order
7. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
8. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
9. Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers
10. Finesse Solutions Expands by Opening Sales and Service Centers
11. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... (PRWEB) October 17, 2014 ... offers a full line of Styrene-Butadiene polymer ... barrier coatings and a variety of other ... provide outstanding performance in these applications.  , ... in performance and cost effectiveness.  SB polymer ...
(Date:10/17/2014)... (PRWEB) October 17, 2014 The North ... concerned market in North America with analysis and forecast ... in 2013, and is expected to reach $1329.6 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. This also provides ...
(Date:10/17/2014)... Mediso stellt den MultiScan ... MultiScan-Produktreihe, das speziell für Forschungsanwendungen in der klinischen ... (Large Field of view Extreme Resolution) mit einem ... Sichtfeld in Breitenrichtung von 15 cm, einer PET-Auflösung ... % soll für die vorklinische Hirnforschung eingesetzt werden. ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 /PRNewswire/ ... - Research and Markets ( http://www.researchandmarkets.com/research/6cbkgn/latest_guidebook ) ... Guidebook for Conducting Medical Device Clinical Evaluation ... to Practices (2014 Edition)"  report to their ... , China,s regulatory framework ...
Breaking Biology Technology:Mallard Creek Polymers Reminds Industry of the Full Line of Styrene-Butadiene Polymer Emulsions 2The North American flexible display market and is expected to reach $1329.6 million by 2018 - New Report by MicroMarket Monitor 2The North American flexible display market and is expected to reach $1329.6 million by 2018 - New Report by MicroMarket Monitor 3Mediso enthüllt neues Forschungswerkzeug MultiScan LFER 150 PET/CT 2Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition) 2Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition) 3
... Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), ... tumor specific data to enhance the value of oncology drugs, today ... 2009. Full details of the Company,s financial results are available in ... , Total revenues for the first quarter of ...
... SINGAPORE, Sept. 14 China Agro-Technology Holdings (OTC ... website which is focused on spotlighting the company,s focus on ... website is located at www.chinaagrotech.com. , , ... Holdings Ltd., headquartered in Singapore, is focused on becoming a ...
... , , ... 14 Tobira Therapeutics Inc., a clinical stage biotechnology ... treatment of life-threatening and life-altering infectious diseases, today announced ... randomized study of TBR-652 in sixty healthy volunteers. ...
Cached Biology Technology:Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 5Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV 2
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2
... calls for policymakers to reduce both nitrogen and phosphorus ... problems in fresh and coastal waters. In the ... argue that dual-nutrient reduction strategies are likely to be ... phosphorus in fresh and coastal water ecosystems. "If ...
... 2009 ― Protecting drinking water and preventing harmful ... many lakes, will require reducing both nitrogen and ... to the sea, management strategies should be implemented ... that focus only on one nutrient will fail. ...
... be exhausting. When fruit flies mate, the females, genes ... an immune reaction starts. This is shown in a ... the scientific publication, Journal of Evolutionary Biology .* ... genomic technology, so-called microarrays, researchers at Uppsala University can ...
Cached Biology News:Nutrient pollution chokes marine and freshwater ecosystems 2
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
Biology Products: